immatics biotechnologies GmbH Cash Flow Conversion Efficiency
immatics biotechnologies GmbH cash flow conversion efficiency. Based on the latest financial reports, immatics biotechnologies GmbH (4A3) has a cash flow conversion efficiency ratio of -0.151x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-60.46 Million ≈ $-70.69 Million USD) by net assets (€399.62 Million ≈ $467.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of immatics biotechnologies GmbH (2019–2025)
Cash flow conversion efficiency of immatics biotechnologies GmbH from 2019 to 2025. This chart illustrates how immatics biotechnologies GmbH's cash flow conversion efficiency has evolved over time, based on yearly financial data. View immatics biotechnologies GmbH stock quote for real-time trading data and today's change.
immatics biotechnologies GmbH Cash Flow Conversion Ratio Explained
immatics biotechnologies GmbH cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
immatics biotechnologies GmbH Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of immatics biotechnologies GmbH ranked by their cash flow conversion efficiency. Also see 4A3 stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Hon Chuan Enterprise Co Ltd
TW:9939
|
0.099x |
|
ITMAX System Berhad
KLSE:5309
|
0.060x |
|
Saregama India Limited
NSE:SAREGAMA
|
0.051x |
|
Neuberger Berman Next Generation Connectivity Fund Inc
NYSE:NBXG
|
N/A |
|
Vor Biopharma Inc
NASDAQ:VOR
|
0.128x |
|
Aevis Victoria SA
SW:AEVS
|
0.037x |
|
Lancy Co Ltd
SHE:002612
|
0.018x |
|
EFORT Intelligent Equipment Co Ltd
SHG:688165
|
-0.095x |
Annual Cash Flow Conversion Efficiency for immatics biotechnologies GmbH (2019–2025)
The table below shows the annual cash flow conversion efficiency of immatics biotechnologies GmbH from 2019 to 2025. Review immatics biotechnologies GmbH free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €484.10 Million ≈ $565.96 Million |
€-176.63 Million ≈ $-206.49 Million |
-0.365x | -32.72% |
| 2024-12-31 | €574.84 Million ≈ $672.05 Million |
€-158.03 Million ≈ $-184.75 Million |
-0.275x | -439.47% |
| 2023-12-31 | €225.08 Million ≈ $263.15 Million |
€18.23 Million ≈ $21.31 Million |
0.081x | -82.76% |
| 2022-12-31 | €213.16 Million ≈ $249.21 Million |
€100.13 Million ≈ $117.06 Million |
0.470x | -88.71% |
| 2021-12-31 | €24.06 Million ≈ $28.13 Million |
€100.13 Million ≈ $117.06 Million |
4.161x | +333.26% |
| 2020-12-31 | €104.26 Million ≈ $121.89 Million |
€100.13 Million ≈ $117.06 Million |
0.960x | +155.26% |
| 2019-12-31 | €-40.84 Million ≈ $-47.74 Million |
€70.97 Million ≈ $82.97 Million |
-1.738x | -- |
About immatics biotechnologies GmbH
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecific… Read more